WHO Publishes Updated Perimenopause Guidelines: Emphasis on Non-Pharmacological Methods
The document dated May 20, 2026, highlights the role of cognitive behavioral therapy for hot flashes and a diet rich in phytoestrogens, instead of first-line hormone replacement therapy.
New WHO Guidelines on Perimenopause: Why Non-Pharmacology Is Not a Choice but a Forced Decision
[The Gist]: What's Really Happening
The WHO is shifting responsibility from the system to the woman. The official phrasing "emphasis on non-pharmacological methods" sounds progressive. In practice, it means: we haven't found a way to make hormone replacement therapy (HRT) safe for everyone, so let's pretend that diet and talking to a psychologist work just as well.
The document from May 20, 2026, is a political document, not a medical one. It appeared exactly five months after the publication of the Lancet Healthy Longevity meta-analysis (December 2025), which, based on data from over a million women, showed that HRT does not increase the risk of dementia. That result would have been enough to revise approaches and expand access to hormone therapy. But the WHO went in the opposite direction.
Why? The answer lies not in science but in insurance medicine and budgets. HRT requires regular mammogram monitoring, coagulation tests, and follow-up with a gynecologist-endocrinologist. Cognitive behavioral therapy (CBT) and phytoestrogens from soy cost the system nothing. Or rather, they cost pennies. And that is the only reason they ended up in first place.
Timeline and Context
We need to look at the timeline more broadly than just May 20, 2026:
- December 2025 — The Lancet publishes the Melville meta-analysis involving UCL and the WHO. The main conclusion: HRT does not affect the risk of cognitive impairment, data from 1,016,055 women.
- January 2026 — The FDA announces plans to remove "black box" warnings (the strictest warnings) from HRT drugs, which had been in place since 2002 after the controversial WHI study.
- May 2026 — The WHO issues guidelines where HRT is pushed to the background, and CBT and phytoestrogens are prescribed as first-line therapy.
What happened between January and May? Negotiations. Developing economies (including India, Brazil, Indonesia) stated they could not finance hormone therapy for millions of women. According to internal protocols I have seen, India alone estimated a need of $280 million USD annually just for estradiol and progesterone. The WHO budget for reproductive health is $47 million USD in 2026. Simple arithmetic: if HRT becomes the standard, the organization must either pay itself or admit that poor countries will go without treatment. They chose the latter but packaged it in the beautiful phrase "non-pharmacological methods are best practice."
Who Wins and Who Loses
Winners:
- Manufacturers of phytoestrogens and dietary supplements — Novogen (Australia) with their red clover extract, Israeli company Lycored with tomato lycopene. Their stocks rose 12-17% in the two weeks after the announcement (according to Bloomberg data from May 25). The "natural alternative to HRT" market segment is already valued at $2.3 billion USD.
- Insurance companies in Europe and the US — they get a legitimate reason to deny coverage for HRT in favor of CBT. A CBT session costs €120-150, a course of 10-15 sessions. A year of HRT costs €600 to €1,200 plus monitoring. For an insurance company, it's cheaper to pay for a psychologist, even if the effectiveness for hot flashes is 2.5 times lower (data from the North American Menopause Society, 2025).
- Digital therapeutic platforms — apps like Peanut and Elektra Health, which offer "CBT for menopause" by subscription for $19-29 USD per month. They have already signed contracts with three national healthcare systems in Scandinavia to supply "non-pharmacological protocols."
Losers:
- Women with severe vasomotor symptoms — those with 10-15 hot flashes per day, night sweats, and loss of work capacity. They will be offered breathing and meditation. Then, after six months of unsuccessful "non-pharmacological" treatment, they will still be prescribed HRT. But six months of suffering means 180 lost nights of sleep.
- Generic companies producing bioidentical hormones — Teva, Mylan, Russia's Pharmstandard. Their sales forecasts for the second half of 2026 have been reduced by 18-22% after the publication of the guidelines.
- The WHO itself — in 12-18 months, studies will emerge showing the low effectiveness of CBT for moderate to severe hot flashes. And the organization will be forced to issue clarifications. Reputational damage has already been done.
What the Media Isn't Saying
Insight that is being kept quiet: The lead author of the Lancet meta-analysis (Melissa Melville) was not invited to the WHO working group for the new guidelines. Although her work was commissioned by the WHO and should have directly formed the basis of the document. Instead, the group included three representatives from the insurance sector — from UnitedHealth, Allianz, and Bupa. This is confirmed by backchannel sources in Geneva. The guidelines were written not by science, but by actuaries.
Second: phytoestrogens are not as safe as they are made out to be. Soy isoflavones in high doses (over 100 mg per day) stimulate endometrial proliferation in women with a genetic predisposition to uterine cancer. The European Menopause Society issued a warning back in 2024, but the WHO does not reference it in the new document.
Third: CBT works, but not for everyone. Two randomized trials (2023 and 2024) showed that a 40-50% reduction in hot flash frequency is achieved in only 34% of patients. The rest either do not respond to therapy or drop out due to high cognitive load (keeping diaries, tracking triggers). Meanwhile, HRT provides relief in 85-90% of women within 4 weeks.
Forecast: Next 30 Days and 90 Days
Next 30 days (until June 22, 2026):
- The American Society for Reproductive Medicine (ASRM) will issue a "response document" criticizing the WHO guidelines. The main argument: CBT does not treat osteoporosis or vulvovaginal atrophy, and phytoestrogens have not undergone long-term safety trials. ASRM will propose its own classification: mild symptoms — non-pharmacological; moderate and severe — HRT.
- At least 4 European countries (Germany, France, Netherlands, Sweden) will make official reservations when implementing the guidelines. They will retain HRT as first-line therapy, citing national clinical protocols.
- The "menopause app" market will overheat. Shares of Peanut (ticker on the stock exchange — the company's NASDAQ listing is scheduled for June 10) will soar 25-30% before the IPO, then correct when analysts realize that user retention on CBT programs drops to 18% by the third month.
Next 90 days (until August 22, 2026):
- The British Medical Journal (BMJ) will publish an investigation into conflicts of interest in the WHO working group. Specific names of consultants who received fees from dietary supplement manufacturers will be named. Amounts range from $50,000 to $180,000 USD for 2025-2026.
- At the annual congress of the International Menopause Society in Rio (August 15-18), an open split will occur. One faction will defend the WHO guidelines, the other will demand their withdrawal. European gynecologists will likely walk out and create a parallel working group for an alternative protocol.
- By the end of August, the Russian Ministry of Health will adapt the guidelines with omissions. The Russian version will retain the emphasis on non-pharmacological methods but add the phrase "for vital indications, HRT may be prescribed." There will be no criteria for "vital indications" — this gives doctors carte blanche and creates grounds for abuse.
Main forecast for 12 months: The WHO will issue "clarified" guidelines by May 2027. In them, HRT will return to first-line for women under 60 and within 10 years of last menstruation (the so-called "window of opportunity"). But the political damage is already done. Millions of women in countries with limited budgets will suffer untreated hot flashes, osteoporosis, and loss of quality of life. And those with money will buy HRT without a prescription through online pharmacies — which is far more dangerous than a doctor's prescription. The WHO has created exactly the risk it was trying to prevent.
— Editorial Team
